Advertisement

Human Respiratory Syncytial Virus: An Introduction

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1442)

Abstract

Human respiratory syncytial virus (RSV) is understood to be a significant human pathogen in infants, young children, and the elderly and the immunocompromised. Over the last decade many important mechanisms contributing to RSV infection, replication, and disease pathogenesis have been revealed; however, there is still insufficient knowledge which has in part hampered vaccine development. Considerable information is accumulating regarding how RSV proteins modulate molecular signaling and immune responses to infection. Understanding how RSV interacts with its host is crucial to facilitate the development of safe and effective vaccines and therapeutic treatments.

In this chapter, we provide a brief introduction into RSV replication, pathogenesis, and host immune response, and summarize the state of RSV vaccine and antiviral compounds in clinical stages of development. This chapter frames features of this book and the molecular methods used for understanding RSV interaction with the host.

Key words

Respiratory syncytial virus RSV proteins Innate immune response Adaptive immune response Vaccine Antiviral compounds 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Krzyzaniak MA et al (2013) Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog 9(4):e1003309PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Oshansky CM et al (2009) The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol 4(3):279–297PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Wright PF (2014) Progress in the prevention and treatment of RSV infection. N Engl J Med 371(8):776–777PubMedCrossRefGoogle Scholar
  4. 4.
    Harris J, Werling D (2003) Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol 5(10):671–680PubMedCrossRefGoogle Scholar
  5. 5.
    Castilow EM, Meyerholz DK, Varga SM (2008) IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol 180(4):2376–2384PubMedCrossRefGoogle Scholar
  6. 6.
    Botosso VF et al (2009) Positive selection results in frequent reversible amino acid replacements in the G protein gene of human respiratory syncytial virus. PLoS Pathog 5(1):e1000254PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Martinelli M et al (2014) Phylogeny and population dynamics of respiratory syncytial virus (Rsv) A and B. Virus Res 189:293–302PubMedCrossRefGoogle Scholar
  8. 8.
    Maggon K, Barik S (2004) New drugs and treatment for respiratory syncytial virus. Rev Med Virol 14(3):149–168PubMedCrossRefGoogle Scholar
  9. 9.
    Kiss G et al (2014) Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex. J Virol 88(13):7602–7617PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Castagne N et al (2004) Biochemical characterization of the respiratory syncytial virus P-P and P-N protein complexes and localization of the P protein oligomerization domain. J Gen Virol 85(Pt 6):1643–1653PubMedCrossRefGoogle Scholar
  11. 11.
    Tiong-Yip CL et al (2014) Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother 58(7):3867–3873PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Noton SL et al (2012) The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter. PLoS Pathog 8(10):e1002980PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Tran TL et al (2007) The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. J Gen Virol 88(Pt 1):196–206PubMedCrossRefGoogle Scholar
  14. 14.
    Galloux M et al (2015) Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein. J Virol 89(7):3484–3496PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Cheng X et al (2005) Overexpression of the M2-2 protein of respiratory syncytial virus inhibits viral replication. J Virol 79(22):13943–13952PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Mitra R et al (2012) The human respiratory syncytial virus matrix protein is required for maturation of viral filaments. J Virol 86(8):4432–4443PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Tayyari F et al (2011) Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 17(9):1132–1135PubMedCrossRefGoogle Scholar
  18. 18.
    Li Y et al (2014) Inhibition of the human respiratory syncytial virus small hydrophobic protein and structural variations in a bicelle environment. J Virol 88(20):11899–11914PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Tripp RA et al (2001) CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2(8):732–738PubMedCrossRefGoogle Scholar
  20. 20.
    Langedijk JP et al (1998) Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology 243(2):293–302PubMedCrossRefGoogle Scholar
  21. 21.
    Haynes LM et al (2003) Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 77(18):9831–9844PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Harcourt J et al (2006) Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 176(3):1600–1608PubMedCrossRefGoogle Scholar
  23. 23.
    Kauvar LM et al (2010) Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2(5):655–661PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Tripp RA et al (2003) The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol 77(11):6580–6584PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Tripp RA, Jones L, Anderson LJ (2000) Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J Virol 74(13):6227–6229PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Tripp RA et al (1999) Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 73(9):7099–7107PubMedPubMedCentralGoogle Scholar
  27. 27.
    Tripp RA et al (2000) Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J Virol 74(4):1614–1622PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Choi Y et al (2012) Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol 25(3):193–203PubMedPubMedCentralGoogle Scholar
  29. 29.
    Miao C et al (2009) Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol 90(Pt 5):1119–1123PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Haynes LM et al (2009) Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 200(3):439–447PubMedCrossRefGoogle Scholar
  31. 31.
    Pastey MK, Crowe JE Jr, Graham BS (1999) RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J Virol 73(9):7262–7270PubMedPubMedCentralGoogle Scholar
  32. 32.
    Gower TL et al (2001) RhoA is activated during respiratory syncytial virus infection. Virology 283(2):188–196PubMedCrossRefGoogle Scholar
  33. 33.
    Kurt-Jones EA et al (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1(5):398–401PubMedCrossRefGoogle Scholar
  34. 34.
    Barik S (2013) Respiratory syncytial virus mechanisms to interfere with type 1 interferons. Curr Top Microbiol Immunol 372:173–191PubMedGoogle Scholar
  35. 35.
    Ling Z, Tran KC, Teng MN (2009) Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol 83(8):3734–3742PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Bourgeois C et al (1998) Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro. J Virol 72(9):7221–7227PubMedPubMedCentralGoogle Scholar
  37. 37.
    Krusat T, Streckert HJ (1997) Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 142(6):1247–1254PubMedCrossRefGoogle Scholar
  38. 38.
    Feldman SA, Hendry RM, Beeler JA (1999) Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 73(8):6610–6617PubMedPubMedCentralGoogle Scholar
  39. 39.
    Techaarpornkul S, Collins PL, Peeples ME (2002) Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 294(2):296–304PubMedCrossRefGoogle Scholar
  40. 40.
    Karron RA et al (1997) Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A 94(25):13961–13966PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Teng MN, Whitehead SS, Collins PL (2001) Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289(2):283–296PubMedCrossRefGoogle Scholar
  42. 42.
    Mastrangelo P, Hegele RG (2013) RSV fusion: time for a new model. Viruses 5(3):873–885PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Levine S, Hamilton R (1969) Kinetics of the respiratory syncytial virus growth cycle in HeLa cells. Arch Gesamte Virusforsch 28(2):122–132PubMedCrossRefGoogle Scholar
  44. 44.
    Hierholzer JC, Tannock GA (1986) Respiratory syncytial virus: a review of the virus, its epidemiology, immune response and laboratory diagnosis. Aust Paediatr J 22(2):77–82PubMedGoogle Scholar
  45. 45.
    Arslanagic E et al (1996) Maturation of respiratory syncytial virus within HEp-2 cell cytoplasm. Acta Virol 40(4):209–214PubMedGoogle Scholar
  46. 46.
    Routledge EG et al (1987) Expression of the respiratory syncytial virus 22K protein on the surface of infected HeLa cells. J Gen Virol 68(Pt 4):1217–1222PubMedCrossRefGoogle Scholar
  47. 47.
    Fearns R, Collins PL (1999) Model for polymerase access to the overlapped L gene of respiratory syncytial virus. J Virol 73(1):388–397PubMedPubMedCentralGoogle Scholar
  48. 48.
    Huang YT, Collins PL, Wertz GW (1985) Characterization of the 10 proteins of human respiratory syncytial virus: identification of a fourth envelope-associated protein. Virus Res 2(2):157–173PubMedCrossRefGoogle Scholar
  49. 49.
    Dickens LE, Collins PL, Wertz GW (1984) Transcriptional mapping of human respiratory syncytial virus. J Virol 52(2):364–369PubMedPubMedCentralGoogle Scholar
  50. 50.
    Kuo L et al (1996) Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus. J Virol 70(10):6892–6901PubMedPubMedCentralGoogle Scholar
  51. 51.
    Harmon SB, Megaw AG, Wertz GW (2001) RNA sequences involved in transcriptional termination of respiratory syncytial virus. J Virol 75(1):36–44PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Krempl C, Murphy BR, Collins PL (2002) Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol 76(23):11931–11942PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Brown G et al (2002) Caveolin-1 is incorporated into mature respiratory syncytial virus particles during virus assembly on the surface of virus-infected cells. J Gen Virol 83(Pt 3):611–621PubMedCrossRefGoogle Scholar
  54. 54.
    Oymar K, Skjerven HO, Mikalsen IB (2014) Acute bronchiolitis in infants, a review. Scand J Trauma Resusc Emerg Med 22:23PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Turner TL et al (2014) Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res 6:217–225PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Szabo SM et al (2013) Elevated risk of asthma after hospitalization for respiratory syncytial virus infection in infancy. Paediatr Respir Rev 13(Suppl 2):S9–S15PubMedCrossRefGoogle Scholar
  57. 57.
    Tourdot S et al (2008) Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization. Clin Exp Allergy 38(6):1016–1024PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Sikkel MB et al (2008) Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J 27(10 Suppl):S63–S70PubMedCrossRefGoogle Scholar
  59. 59.
    Kallal LE, Lukacs NW (2008) The role of chemokines in virus-associated asthma exacerbations. Curr Allergy Asthma Rep 8(5):443–450PubMedCrossRefGoogle Scholar
  60. 60.
    Peebles RS Jr, Graham BS (2005) Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2(2):110–115PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Gern JE (2003) Mechanisms of virus-induced asthma. J Pediatr 142(Suppl 2):S9–S13, discussion S13–4PubMedCrossRefGoogle Scholar
  62. 62.
    Domachowske JB et al (2000) Respiratory syncytial virus infection induces expression of the anti-apoptosis gene IEX-1L in human respiratory epithelial cells. J Infect Dis 181(3):824–830PubMedCrossRefGoogle Scholar
  63. 63.
    Kotelkin A et al (2003) Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol 77(17):9156–9172PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Lindemans CA et al (2006) Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism. J Immunol 176(9):5529–5537PubMedCrossRefGoogle Scholar
  65. 65.
    Monick MM et al (2005) Activation of the epidermal growth factor receptor by respiratory syncytial virus results in increased inflammation and delayed apoptosis. J Biol Chem 280(3):2147–2158PubMedCrossRefGoogle Scholar
  66. 66.
    Murawski MR et al (2009) Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 83(3):1492–1500PubMedCrossRefGoogle Scholar
  67. 67.
    Xie XH et al (2009) Lipopolysaccharide induces IL-6 production in respiratory syncytial virus-infected airway epithelial cells through the toll-like receptor 4 signaling pathway. Pediatr Res 65(2):156–162PubMedCrossRefGoogle Scholar
  68. 68.
    Monick MM et al (2003) Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 278(52):53035–53044PubMedCrossRefGoogle Scholar
  69. 69.
    Becker Y (2006) Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy—a review. Virus Genes 33(2):235–252PubMedGoogle Scholar
  70. 70.
    Bruder D, Srikiatkhachorn A, Enelow RI (2006) Cellular immunity and lung injury in respiratory virus infection. Viral Immunol 19(2):147–155PubMedCrossRefGoogle Scholar
  71. 71.
    Groothuis JR (1994) The role of RSV neutralizing antibodies in the treatment and prevention of respiratory syncytial virus infection in high-risk children. Antiviral Res 23(1):1–10PubMedCrossRefGoogle Scholar
  72. 72.
    Sakurai H et al (1999) Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol 73(4):2956–2962PubMedPubMedCentralGoogle Scholar
  73. 73.
    Boyoglu-Barnum S et al (2013) A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol 87(20):10955–10967PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Caidi H et al (2012) Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice. PLoS One 7(12):e51485PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Cherrie AH et al (1992) Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J Virol 66(4):2102–2110PubMedPubMedCentralGoogle Scholar
  76. 76.
    Openshaw PJ (1995) Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am J Respir Crit Care Med 152(4 Pt 2):S59–S62PubMedCrossRefGoogle Scholar
  77. 77.
    Tripp RA, Anderson LJ (1998) Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine. J Virol 72(11):8971–8975PubMedPubMedCentralGoogle Scholar
  78. 78.
    Connors M et al (1992) Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 66(12):7444–7451PubMedPubMedCentralGoogle Scholar
  79. 79.
    Graham BS et al (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88(3):1026–1033PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Johnson TR, Graham BS (1999) Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 73(10):8485–8495PubMedPubMedCentralGoogle Scholar
  81. 81.
    Varga SM, Wissinger EL, Braciale TJ (2000) The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol 165(11):6487–6495PubMedCrossRefGoogle Scholar
  82. 82.
    Varga SM et al (2001) Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 15(4):637–646PubMedCrossRefGoogle Scholar
  83. 83.
    Wissinger EL et al (2008) Proliferative expansion and acquisition of effector activity by memory CD4+ T cells in the lungs following pulmonary virus infection. J Immunol 180(5):2957–2966PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Tripp RA (2004) Pathogenesis of respiratory syncytial virus infection. Viral Immunol 17(2):165–181PubMedCrossRefGoogle Scholar
  85. 85.
    Luongo C et al (2013) Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol 87(4):1985–1996PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Cheng X et al (2001) Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys. Virology 283(1):59–68PubMedCrossRefGoogle Scholar
  87. 87.
    Luongo C et al (2012) Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 86(19):10792–10804PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Gomez M et al (2009) Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 28(7):655–658PubMedCrossRefGoogle Scholar
  89. 89.
    Nelson CL, Tang RS, Stillman EA (2013) Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells. Vaccine 31(36):3756–3762PubMedCrossRefGoogle Scholar
  90. 90.
    Yang CF et al (2013) Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine 31(26):2822–2827PubMedCrossRefGoogle Scholar
  91. 91.
    Glenn GM et al (2013) Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 31(3):524–532PubMedCrossRefGoogle Scholar
  92. 92.
    Challa S et al (2015) Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother 59(2):1080–1087PubMedCrossRefGoogle Scholar
  93. 93.
    DeVincenzo JP et al (2014) Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371(8):711–722PubMedCrossRefGoogle Scholar
  94. 94.
    Mackman RL et al (2015) Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem 58(4):1630–1643PubMedCrossRefGoogle Scholar
  95. 95.
    Alvarez R et al (2009) RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 53(9):3952–3962PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    DeVincenzo J et al (2008) Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 77(3):225–231PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Infectious Diseases, College of Veterinary Medicine, Animal Health Research CenterUniversity of GeorgiaAthensUSA

Personalised recommendations

Cite protocol

Buy options